MindWalk Holdings Corp.
HYFTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, MindWalk Holdings Corp. (HYFT) is listed under Biotechnology. The $63.4M market capitalization puts HYFT squarely in micro-cap range for its industry. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology.
Market Cap
$63.4M
Beta
0.83
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.24
EPS (Fwd)
—
ROE
-85.4%
ROA
-28.4%
Cash
$11.3M
Total Debt
$3.5M
Free CF
-$5.5M
52W Change
-30.9%
Annual Financials
Cash vs Debt
Where HYFT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HYFT finished 2.92% below its 150-day moving average ($1.37) and 12.50% below its 200-day moving average ($1.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HYFT overbought or oversold?
At the September 3, 2026 close, HYFT's RSI(14) was 45.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $11.3M in cash comfortably exceeding the $3.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$5.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -85.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $20.7M to $15.6M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HYFT.